Neurology

Fuel and Signals: The Genetics Behind the Movements

At a Glance

The specific gene can show whether attacks involve low brain fuel or unstable nerve signals, helping clinicians choose targeted care, such as a ketogenic diet for SLC2A1-related disease or medicines for PRRT2- and CACNA1A-related symptoms.

When your child is diagnosed with a complex movement disorder, the doctor is often looking at how the brain manages two critical tasks: how it gets its energy and how it sends its signals. This condition is typically linked to a small group of specific genes—SLC2A1, PRRT2, PNKD, CACNA1A, and KCNA1—each of which plays a different role in these processes ^[1]^[2]. Note: These biological mechanisms are simplified analogies. The clinical phenotype and specific genetic variant matter deeply, and not every patient will find a clear genetic match on a testing panel.

The Energy Crisis: SLC2A1 (Glut1)

The SLC2A1 gene provides instructions for making a protein called Glut1, which is the primary “gatekeeper” that moves glucose (sugar) from the blood into the brain ^[3].

If this protein isn’t working correctly, the brain experiences a chronic energy shortage known as neuroglycopenia ^[4]. While blood sugar levels might look normal, the brain isn’t getting the fuel it needs. This “energy crisis” can cause the brain to misfire, leading to attacks of involuntary movement, balance issues (ataxia), or stiffness (spasticity) ^[5]. These attacks are often triggered by fasting or long periods of exercise, when the brain’s energy demands are highest ^[6].

The Signaling Static: PRRT2, PNKD, CACNA1A, and KCNA1

While SLC2A1 is about fuel, the other genes are about the electrical and chemical signals the brain uses to communicate.

PRRT2 and PNKD (The Synapse Controllers): These genes help control how brain cells release chemicals called neurotransmitters at the synapse (the gap between nerve cells) ^[7]. When they malfunction, the brain can become “hyperexcitable,” leading to sudden bursts of movement, especially when triggered by a sudden start or surprise ^[8]^[9].
CACNA1A and KCNA1 (The Ion Channels): These genes are part of the brain’s electrical system, acting as “ion channels” that let calcium or potassium in and out of cells ^[10]^[11]. If these channels are “leaky” or “blocked,” it disrupts the electrical balance, leading to the loss of coordination seen in episodic ataxia ^[12].

Why the Specific Gene Matters for Treatment

Finding the exact genetic cause is essential because the treatments for an energy problem are completely different from the treatments for a signaling problem.

For SLC2A1 (Glut1 Deficiency): Since the brain can’t use glucose properly, doctors often use a ketogenic diet ^[13]. This high-fat, low-carbohydrate diet forces the body to make ketone bodies, an alternative fuel that the brain can use instead of glucose ^[14].
For PRRT2: Because this involves signaling “static,” small doses of sodium-channel blockers like carbamazepine are often highly effective at stabilizing the signals and preventing attacks for PKD ^[1]^[15].
For CACNA1A: Medications like acetazolamide are frequently used to help stabilize the electrical environment in the brain and reduce ataxia episodes in EA2 ^[12].

Understanding Inheritance

You may wonder how this happened. These conditions follow several patterns, and genetic counseling is recommended:

Autosomal Dominant: This means a person only needs one changed copy of the gene to have the condition. Sometimes it is inherited from a parent who might have very mild symptoms or even no symptoms at all (reduced penetrance) due to variable expressivity or parental mosaicism ^[16]^[17].
De Novo Mutation: In many cases, the genetic change is “new” (de novo) in the child, meaning neither parent carries the mutation ^[18]^[19]. While this usually lowers recurrence considerations, it does not eliminate them.

Knowing the genetic cause doesn’t just help with treatment; it helps your medical team understand the biological “why” behind your child’s symptoms, allowing for a care plan that addresses the root cause rather than just the outward movements.

Common questions in this guide

What genes are associated with paroxysmal dystonic choreathetosis and episodic ataxia?

Several genes can be involved, including SLC2A1, PRRT2, PNKD, CACNA1A, and KCNA1. SLC2A1 mainly affects how the brain gets fuel, while the other genes affect communication or electrical signaling between nerve cells. The specific gene change and your child’s symptoms matter because not every genetic panel finds a clear cause.

Why can fasting or prolonged exercise trigger my child’s attacks?

With an SLC2A1 change, glucose may not move into the brain efficiently, so the brain can run short of fuel even when blood sugar is normal. Fasting and prolonged exercise increase energy needs and can make involuntary movements or balance problems more likely.

Would a ketogenic diet help if my child has an SLC2A1 change?

A ketogenic diet provides ketones, an alternative fuel the brain can use when glucose transport is impaired. It is a medical treatment that should be planned and monitored by the child’s healthcare team rather than started without supervision.

What does a PRRT2 gene change mean for treatment?

PRRT2-related signaling problems can make nerve cells overactive and cause sudden movement attacks, often after a quick movement or surprise. Carbamazepine, a medicine that helps stabilize nerve signals, is often effective for paroxysmal kinesigenic dyskinesia, but the child’s clinician should match treatment to the symptoms and gene change.

How are CACNA1A-related episodic ataxia attacks treated?

CACNA1A affects an electrical channel in nerve cells and can contribute to episodes of poor coordination. Acetazolamide is frequently used to reduce episodes in episodic ataxia type 2, but treatment decisions depend on the child’s clinical findings.

Could one of us have passed this gene change to our child without knowing it?

Yes. Some of these conditions can follow an autosomal dominant pattern, meaning one changed copy of a gene can be enough, and a parent may have very mild or no symptoms because of reduced penetrance or variable expression. Other changes arise de novo in the child, so genetic counseling can help clarify inheritance and future pregnancy considerations.

Why does finding the exact gene matter for my child’s care?

Different gene changes affect brain energy or nerve signaling, so the most appropriate treatment may differ. The result can help clinicians decide whether to consider a ketogenic diet, carbamazepine, acetazolamide, or another approach and can guide family counseling.

Get notified when new evidence is published on Paroxysmal dystonic choreathetosis with episodic ataxia and spasticity.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (19)

1
Paroxysmal movement disorders - practical update on diagnosis and management.
De Gusmao CM, Silveira-Moriyama L
Expert review of neurotherapeutics 2019; (19(9)):807-822 doi:10.1080/14737175.2019.1648211.
PMID: 31353980
2
Paroxysmal Movement Disorders.
Harvey S, King MD, Gorman KM
Frontiers in neurology 2021; (12()):659064 doi:10.3389/fneur.2021.659064.
PMID: 34177764
3
One Molecule for Mental Nourishment and More: Glucose Transporter Type 1-Biology and Deficiency Syndrome.
Vulturar R, Chiș A, Pintilie S, et al.
Biomedicines 2022; (10(6)) doi:10.3390/biomedicines10061249.
PMID: 35740271
4
An in vitro model of glucose transporter 1 deficiency syndrome at the blood-brain barrier using induced pluripotent stem cells.
Pervaiz I, Zahra FT, Mikelis CM, Al-Ahmad AJ
Journal of neurochemistry 2022; (162(6)):483-500 doi:10.1111/jnc.15684.
PMID: 35943296
5
Exploring diazoxide and continuous glucose monitoring as treatment for Glut1 deficiency syndrome.
Logel SN, Connor EL, Hsu DA, et al.
Annals of clinical and translational neurology 2021; (8(11)):2205-2209 doi:10.1002/acn3.51462.
PMID: 34612610
6
Differentiating non-epileptic seizures from epileptic seizures in Glut1 deficiency syndrome.
Ito Y, Nakatsukasa H, Toyoma Y, et al.
Developmental medicine and child neurology 2024; (66(11)):1466-1475 doi:10.1111/dmcn.15942.
PMID: 38655597
7
PRRT2 Is a Key Component of the Ca(2+)-Dependent Neurotransmitter Release Machinery.
Valente P, Castroflorio E, Rossi P, et al.
Cell reports 2016; (15(1)):117-131 doi:10.1016/j.celrep.2016.03.005.
PMID: 27052163
8
PRRT2 controls neuronal excitability by negatively modulating Na+ channel 1.2/1.6 activity.
Fruscione F, Valente P, Sterlini B, et al.
Brain : a journal of neurology 2018; (141(4)):1000-1016 doi:10.1093/brain/awy051.
PMID: 29554219
9
Protein mutated in paroxysmal dyskinesia interacts with the active zone protein RIM and suppresses synaptic vesicle exocytosis.
Shen Y, Ge WP, Li Y, et al.
Proceedings of the National Academy of Sciences of the United States of America 2015; (112(10)):2935-41 doi:10.1073/pnas.1501364112.
PMID: 25730884
10
A Single Amino Acid Deletion (ΔF1502) in the S6 Segment of CaV2.1 Domain III Associated with Congenital Ataxia Increases Channel Activity and Promotes Ca2+ Influx.
Bahamonde MI, Serra SA, Drechsel O, et al.
PloS one 2015; (10(12)):e0146035 doi:10.1371/journal.pone.0146035.
PMID: 26716990
11
New insights into the pathogenesis and therapeutics of episodic ataxia type 1.
D'Adamo MC, Hasan S, Guglielmi L, et al.
Frontiers in cellular neuroscience 2015; (9()):317 doi:10.3389/fncel.2015.00317.
PMID: 26347608
12
Episodic Ataxias: Primary and Secondary Etiologies, Treatment, and Classification Approaches.
Hassan A
Tremor and other hyperkinetic movements (New York, N.Y.) 2023; (13()):9 doi:10.5334/tohm.747.
PMID: 37008993
13
Diagnosis and treatment recommendations for glucose transporter 1 deficiency syndrome.
Zhang MJ, Wu , Yu LF, et al.
World journal of pediatrics : WJP 2025; (21(2)):149-158 doi:10.1007/s12519-024-00864-5.
PMID: 39745620
14
GLUT-1DS resistant to ketogenic diet: from clinical feature to in silico analysis. An exemplificative case report with a literature review.
Falsaperla R, Sortino V, Vitaliti G, et al.
Neurogenetics 2024; (25(2)):69-78 doi:10.1007/s10048-023-00742-8.
PMID: 38190079
15
Paroxysmal Dyskinesias in Paediatric Age: A Systematic Review.
Pisanò G, Gnazzo M, Sigona G, et al.
Journal of clinical medicine 2025; (14(17)) doi:10.3390/jcm14175925.
PMID: 40943684
16
Glucose Transporter Deficiency Syndrome Type 1 (Glut1-DS): New Insights From a Brazilian Cohort of Patients.
Sobrinho LMF, Fontana JC, Lorea CF, et al.
JIMD reports 2026; (67(5)):e70113 doi:10.1002/jmd2.70113.
PMID: 42638834
17
Clinical spectrum and genotype-phenotype correlations in PRRT2 Italian patients.
Balagura G, Riva A, Marchese F, et al.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2020; (28()):193-197 doi:10.1016/j.ejpn.2020.06.005.
PMID: 32651081
18
Efficacy and safety evaluation of ketogenic diet therapy in patients with glucose transporter type 1 deficiency syndrome.
Wang M, Liu L, Shang L, et al.
Frontiers in nutrition 2026; (13()):1920521 doi:10.3389/fnut.2026.1920521.
PMID: 42824025
19
CACNA1A Gene Variants in Eight Chinese Patients With a Wide Range of Phenotypes.
Zhang L, Wen Y, Zhang Q, et al.
Frontiers in pediatrics 2020; (8()):577544 doi:10.3389/fped.2020.577544.
PMID: 33425808

This page is for informational purposes only and does not constitute medical advice. A pediatric neurologist and genetics team should interpret your child’s results before any diet or medication changes.